查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552893

糖尿病相關眼部保健市場規模、佔有率和趨勢分析報告：按應用、類型、最終用途、地區、細分市場預測，2024-2030

Diabetes Associated Ophthalmic Treatment Market Size, Share & Trends Analysis Report By Application, By Type (Drugs, Devices), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

糖尿病相關眼保健市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球糖尿病相關眼部保健市場規模預計將達到 513.3 億美元，2024 年至 2030 年複合年成長率為 6.9%。

II 型糖尿病盛行率的增加、老年人口的增加以及早期檢測技術的可用性是推動成長的一些因素。再加上對技術進步和早期診斷的認知不斷提高，有助於提高現有治療方案的成功率。評估用於預防和管理這些眼科疾病的新藥和設備的臨床試驗數量不斷增加，預計將在未來幾年推動市場成長。

與 COVID-19 相關的糖尿病和眼科併發症預計將推動糖尿病相關眼科治療方法市場的發展。 COVID-19 對糖尿病有長期影響。因此，預計未來幾年對治療方法的需求將會增加。政府和非營利組織加強提高人們對糖尿病相關眼疾的認知，預計將推動治療設備的採用。此外，世衛組織和以色列國防軍正在共同努力，透過提供便利的治療設施來預防和管理糖尿病，並改善世界各地人們的生活品質。

糖尿病相關眼保健市場報告亮點：

  • 到 2023 年，糖尿病視網膜病變領域將佔據最大的收益佔有率，其次是糖尿病相關的黃斑部病變和青光眼。
  • 由於全球市場存在主要企業、滲透率高以及開發創新藥物的臨床試驗數量不斷增加等因素，藥品細分市場將在2023年佔據市場主導地位並收益佔有率。
  • 與其他醫療機構相比，由於患者就診數量不斷增加以及醫院基礎設施先進，預計醫院行業在預測期內將呈現最快的成長速度。糖尿病住院人數的增加正在推動需求並推動該領域的成長。
  • 北美地區佔據市場最大的收益佔有率，預計在收益預測期內將保持其主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 糖尿病相關眼部保健市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 糖尿病相關眼部保健市場分析工具
    • 波特的分析
    • PESTEL分析

第4章 糖尿病相關眼科治療市場：按應用估計與趨勢分析

  • 細分儀表板
  • 糖尿病相關眼部保健市場：2023 年和 2030 年應用變化分析
  • 乾眼症
    • 2018-2030 年收益估計與預測
  • 青光眼
    • 2018-2030 年收益估計與預測
  • 眼睛過敏和感染疾病
    • 2018-2030 年收益估計與預測
  • 糖尿病視網膜病變
    • 2018-2030 年收益估計與預測
  • 糖尿病黃斑部病變
    • 2018-2030 年收益估計與預測
  • 葡萄膜炎
    • 2018-2030 年收益估計與預測
  • 白內障
    • 2018-2030 年收益估計與預測
  • 糖尿病黃斑部水腫
    • 2018-2030 年收益估計與預測
  • 其他
    • 2018-2030 年收益估計與預測

第5章 糖尿病相關眼科治療市場：按類型估計和趨勢分析

  • 細分儀表板
  • 糖尿病相關眼科治療市場：類型分析，2023 年和 2030 年
  • 藥品
  • 裝置

第6章 糖尿病相關眼科治療市場：依最終用途分類的估計與趨勢分析

  • 細分儀表板
  • 糖尿病相關眼部治療市場：最終用途和趨勢分析，2023 年和 2030 年
  • 醫院
  • 眼科中心
  • 門診中心
  • 其他

第7章 糖尿病相關眼科治療市場：區域估計與趨勢分析

  • 2023 年及 2030 年糖尿病相關眼保健市場佔有率（按地區）
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Alcon
    • Johnson &Johnson Services, Inc.
    • Bausch Health
    • F. Hoffmann-La Roche Ltd
    • Allergan
    • Bayer AG
    • Santen Pharmaceutical Co. Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Genentech, Inc.
    • Carl Zeiss Meditec
    • Lumenis
    • Ellex Medical Lasers Ltd.
    • IRIDEX Corp.
    • Topcon Corp.
    • Abbott Medical Optics
    • Quantel
簡介目錄
Product Code: GVR-4-68039-553-5

Diabetes Associated Ophthalmic Treatment Market Growth & Trends:

The global diabetes associated ophthalmic treatment market size is expected to reach USD 51.33 billion by 2030, registering to grow at a CAGR of 6.9% from 2024 to 2030 according to a new report by Grand View Research, Inc. The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.

COVID-19 related diabetic and ophthalmic complications are expected to boost the market for diabetes associated ophthalmic treatment methods. COVID-19 has a long-term effect on diabetic conditions. This is expected to increase the demand for treatment procedures in upcoming years. An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.

Diabetes Associated Ophthalmic Treatment Market Report Highlights:

  • The diabetic retinopathy segment has captured the largest revenue share in 2023 followed by diabetic associated macular degeneration and glaucoma
  • The drugs segment dominated the market and accounted for the highest revenue share in 2023 owing to factors such as the presence of major key players operating in the global market, high adoption rate, increased clinical trials to develop innovative drugs
  • The hospitals segment is predicted to witness the fastest growth rate over the forecast timeframe due to the increasing number of patient visits and advanced infrastructure in hospitals as compared to other healthcare facilities. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment, thereby propelling the growth
  • North America held the largest revenue share in the market and is expected to maintain its dominance over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. The Diabetes Associated Ophthalmic Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. The Diabetes Associated Ophthalmic Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Diabetes Associated Ophthalmic Treatment Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Diabetes Associated Ophthalmic Treatment Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Dry Eye Syndrome
    • 4.3.1. Dry Eye Syndrome Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Glaucoma
    • 4.4.1. Glaucoma Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Eye Allergy & Infection
    • 4.5.1. Eye Allergy & Infection Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Diabetic Retinopathy
    • 4.6.1. Diabetic Retinopathy Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Diabetic associated Macular Degeneration
    • 4.7.1. Diabetic associated Macular Degeneration Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Uveitis
    • 4.8.1. Uveitis Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Cataract
    • 4.9.1. Cataract Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Diabetic Macular Edema
    • 4.10.1. Diabetic Macular Edema Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Associated Ophthalmic Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Diabetes Associated Ophthalmic Treatment Market: Type Analysis, 2023 & 2030 (USD Billion)
  • 5.3. Drugs
    • 5.3.1. Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Devices
    • 5.4.1. Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Diabetes Associated Ophthalmic Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Diabetes Associated Ophthalmic Treatment Market: End Use & Trend Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ophthalmic Centres
    • 6.4.1. Ophthalmic Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Ambulatory Centres
    • 6.5.1. Ambulatory Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Diabetes Associated Ophthalmic Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Diabetes Associated Ophthalmic Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. Europe
    • 7.2.1. UK Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. Germany
      • 7.2.2.1. Germany Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. France
      • 7.2.3.1. France Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Italy
      • 7.2.4.1. Italy Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5. Spain
      • 7.2.5.1. Spain Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6. Denmark
      • 7.2.6.1. Denmark Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7. Sweden
      • 7.2.7.1. Sweden Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8. Norway
      • 7.2.8.1. Norway Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Middle East and Africa
    • 7.3.1. South Africa Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Saudi Arabia
      • 7.3.2.1. Saudi Arabia Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. UAE
      • 7.3.3.1. UAE Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Kuwait
      • 7.3.4.1. Kuwait Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Alcon
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Bausch Health
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Allergan
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Santen Pharmaceutical Co. Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Novartis AG
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Genentech, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Carl Zeiss Meditec
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Lumenis
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. Ellex Medical Lasers Ltd.
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. IRIDEX Corp.
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives
    • 8.4.15. Topcon Corp.
      • 8.4.15.1. Participant's Overview
      • 8.4.15.2. Financial Performance
      • 8.4.15.3. Product Benchmarking
      • 8.4.15.4. Recent Developments/ Strategic Initiatives
    • 8.4.16. Abbott Medical Optics
      • 8.4.16.1. Participant's Overview
      • 8.4.16.2. Financial Performance
      • 8.4.16.3. Product Benchmarking
      • 8.4.16.4. Recent Developments/ Strategic Initiatives
    • 8.4.17. Quantel
      • 8.4.17.1. Participant's Overview
      • 8.4.17.2. Financial Performance
      • 8.4.17.3. Product Benchmarking
      • 8.4.17.4. Recent Developments/ Strategic Initiatives